NCT01217632 - A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Liver Fibrosis Due to Chronic Hepatitis B Infection

Interventions

DRUG

FG-3019

FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.

DRUG

Placebo

Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.

DRUG

Entecavir

Trial Locations (9)

Siriraj Hospital, Siriaj

Maharaj Nakorn Chiang Mai Hospital, Amphur Muang

Songklanagarind Hospital, Amphur Hatyai

Queen Mary Hospital, Pokfulam

Ruttonjee Hospital, Wan Chai

Princess Margaret Hospital, Kowloon

Prince of Wales Hospital, Shatin

Tuen Mun Hospital, New Territories

Alice Ho Miu Ling Nethersole Hospital, Tai Po